Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
ACS Chem Biol. 2013 Dec 20;8(12):2635-42. doi: 10.1021/cb400630z. Epub 2013 Oct 21.

Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2.

Author information

  • 1Chemical Genetics Laboratory, ‡Zhang Initiative Research Unit, §Antibiotics Laboratory, RIKEN, ∥Drug Discovery Platforms Cooperation Division, ⊥Chemical Biology Research Group, #Chemical Genomics Research Group, RIKEN Center for Sustainable Resource Science , 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.

Abstract

Conjugation of small ubiquitin-like modifier (SUMO) to protein (SUMOylation) regulates multiple biological systems by changing the functions and fates of a large number of proteins. Consequently, abnormalities in SUMOylation have been linked to multiple diseases, including breast cancer. Using an in situ cell-based screening system, we have identified spectomycin B1 and related natural products as novel SUMOylation inhibitors. Unlike known SUMOylation inhibitors such as ginkgolic acid, spectomycin B1 directly binds to E2 (Ubc9) and selectively blocks the formation of the E2-SUMO intermediate; that is, Ubc9 is the direct target of spectomycin B1. Importantly, either spectomycin B1 treatment or Ubc9 knockdown inhibited estrogen-dependent proliferation of MCF7 human breast-cancer cells. Our findings suggest that Ubc9 inhibitors such as spectomycin B1 have potential as therapeutic agents against hormone-dependent breast cancers.

PMID:
24143955
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Write to the Help Desk